Semaglutide reduced insulin requirements within the first week in type 1 diabetes pump users, primarily because patients ate less, requiring prompt pump setting adjustments to avoid hypoglycemia.
Insulin reduced by day 7Semaglutide's appetite-suppressing effects began reducing insulin requirements within the first week in type 1 diabetes pump users, highlighting the need for rapid pump adjustments
What the researchers found
In 26 adults with type 1 diabetes on insulin pump therapy, semaglutide rapidly reduced total and bolus insulin requirements — significantly by day 7 — while basal insulin reductions became significant by day 32. By day 77, carbohydrate ratios increased 4.1%, correction factors increased 11.2%, and basal rates decreased 7.9%. The insulin reductions were primarily driven by reduced food intake (less carbohydrate consumption) rather than improved insulin sensitivity.
Despite these rapid changes, hypoglycemia was rarely above 4% of time during follow-ups, suggesting that CGM and automated insulin delivery technology helped mitigate hypoglycemia risk — though active pump parameter adjustments were still needed.
Why it matters
Semaglutide is not approved for type 1 diabetes, but its appetite-suppressing effects are leading to off-label use in T1D patients with overweight/obesity. This study reveals how quickly insulin needs change — within the first week — creating a hypoglycemia risk if pump settings aren't adjusted promptly. The data provides practical guidance for the growing number of T1D patients and clinicians using GLP-1 peptide drugs off-label alongside insulin pumps.
The numbers in context
n=26 · Bolus insulin reduced by day 7 · Basal reduced by day 32 · Carb ratios +4.1% · Correction factors +11.2% · Basal rates -7.9% · Hypo time rarely >4% · 81% on AID at baseline
How the study worked
Post-hoc analysis of a double-blinded, randomized, crossover trial comparing semaglutide (up to 1 mg) versus placebo in T1D adults on insulin pump therapy with CGM. The first 11 of 15 weeks were analyzed, during which participants used routine pump therapy. Remote follow-ups were conducted at days 7, 21, 32, 56, 63, and 77. Changes in total, basal, and bolus insulin; carbohydrate input; and pump parameters were assessed relative to baseline.
Who was studied
Adults with type 1 diabetes on insulin pump therapy, 100% using CGM, 81% using automated insulin delivery
What this study cannot tell us
Small sample (n=26). Post-hoc analysis — the trial was not designed to specifically study insulin requirement changes. Only 11 of 15 weeks analyzed. The crossover design means each participant received both semaglutide and placebo, but the analysis focused on semaglutide periods. Results may not generalize to patients without CGM or automated insulin delivery, where hypoglycemia risk would likely be higher. Semaglutide is off-label in T1D.
How to read the evidence
Post-hoc analysis of a small (n=26) double-blinded, randomized, crossover trial. Well-designed original study but the analysis was secondary and the sample is small. Provides practical insights rather than definitive efficacy data.
When this study was published
Published in 2026 with data from a recent crossover trial, this is among the first detailed analyses of how semaglutide affects insulin pump therapy in T1D — a rapidly emerging clinical scenario.
The bigger picture
GLP-1 peptide drugs are increasingly used off-label in type 1 diabetes, creating an urgent need for practical management guidance. This study demonstrates that the dominant mechanism in T1D is appetite suppression (reduced carb intake → less bolus insulin) rather than improved insulin sensitivity — an important distinction from type 2 diabetes. As combined use of GLP-1 drugs and insulin pumps becomes more common, studies like this help establish safe prescribing practices.
Questions still open
- Should pump parameter adjustment protocols be standardized for T1D patients initiating GLP-1 agonists?
- Would patients without automated insulin delivery face significantly higher hypoglycemia risk with semaglutide?
- Does semaglutide provide long-term glycemic benefits in T1D beyond the initial weight and appetite effects?
Common questions
Why would someone with type 1 diabetes take semaglutide?
Why is the rapid insulin reduction risky?
Read the original research
Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.
Diabetes, obesity & metabolism, 28(1), 427-433
Citation
Pasqua, Melissa-Rosina; Tsoukas, Michael A; Haidar, Ahmad. (2026). Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.. Diabetes, obesity & metabolism, 28(1), 427-433. https://doi.org/10.1111/dom.70213